Search results

AbstractPerson centered medicine has emerged as a response to the organ specific, technical and fragmented medical treatment and care that has evolved during the last century in health care systems worldwide. Nevertheless, person centered medicine is not a new concept, as it is rooted in ancient medicine, exemplified by the medical culture of the ancient Greeks. The main components of Person Centered Medicine described here are the cornerstone for successful medical treatment and care. The physician needs to use his communicative skills for this purpose, adhere to attentive, empathic listening, be aware of the cultural, social and educational background of the patient and understand the expectations of the patient for the therapy ahead. He must place the narrative of the patient at the center of clinical evaluation. For this to be possible, the physician needs to have the necessary professional competence and to adhere to the basic ethical principles of medicine. He needs to collaborate not only with the patient, and in some instances with his or her family, but also with other health care workers, whether in a close therapeutic team or with individual professionals. He needs to critically evaluate evidence‐based medicine that is most often presented by various, complicated statistics and to adapt the results of research to his patients in a person centered fashion. For this to be possible, the curricula of Medical Faculties, as well as to mainstream, continuous professional development programs, needs to include the components of Person Centered Medicine.

To access publisher's full text version of this article click on the hyperlink at the bottom of the page ; There is little evidence on the long-term association between physical activity (PA) and depressive symptoms in old age. We examined the association of midlife PA and depressive symptoms in late life. ; A large community-based population residing in Reykjavik, Iceland, participated in a longitudinal study with an average of 25 years of follow up. Midlife PA was categorized as active and inactive groups (n = 4,140, Active = 1,292, Inactive = 2,848, mean age 52±7 years). The main outcome had six or higher depressive symptoms assessed by the 15-item Geriatric Depression scale. Participants who had a history of depression (n = 226), and were diagnosed with dementia (n = 393), and had incomplete cognitive data (n = 595) and incomplete analytical data (n = 422) were excluded. Level of weekly PA was ascertained by a questionnaire at midlife. Depressive symptoms were assessed on average 25 (±4) years later. ; After controlling for demographic and health-related risk factors, those who were active at midlife were less likely to have high level of depressive symptomatology (6 or higher Geriatric Depression scale scores, odds ratio = 0.58, 95% confidence interval: 0.41-0.83, p < .005) compared with those who were inactive in midlife. After full adjustment of three domains of late-life cognitive function the results remained significant (odds ratio = 0.61, 95% confidence interval: 0.43-0.86, p = .005). ; Our study shows that midlife PA is associated with lower depressive symptoms 25 years later. Participating in regular PA in midlife may improve mental health in late life. ; National Institutes of Health/N01-AG-12100 National Institute on Aging Intramural Research Program Icelandic Heart Association Landspitali University Hospital Icelandic Parliament

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download ; A large fraction of genetic risk factors for Alzheimer's Disease (AD) is still not identified, limiting the understanding of AD pathology and study of therapeutic targets. We conducted a genome-wide association study (GWAS) of AD cases and controls of European descent from the multi-center DemGene network across Norway and two independent European cohorts. In a two-stage process, we first performed a meta-analysis using GWAS results from 2,893 AD cases and 6,858 cognitively normal controls from Norway and 25,580 cases and 48,466 controls from the International Genomics of Alzheimer's Project (IGAP), denoted the discovery sample. Second, we selected the top hits (p < 1 × 10 ; Research Council of Norway (RCN) EU JPND Program ApGeM RCN Grant South-East Norway Health Authority Norwegian Health Association KG Jebsen Foundation European Union European Community PIAPP-GA-2011-286213 PsychDPC French National Foundation on Alzheimer's disease and related disorders LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Universite de Lille 2 Lille University Hospital Medical Research Council Alzheimer's Research UK Wellcome Trust German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) NIH/NIA NIA AGES NHLBI Icelandic Heart Association Erasmus Medical Center Erasmus University Alzheimer's Association